Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 855-863

  Karuna, Ratna ^a,b   Park, Rebekka ^b,c   Othman, Alaa ^a,b   Holleboom, Adriaan G ^d   Motazacker, Mohammad Mahdi ^d   Sutter, Iryna ^a,b   Kuivenhoven, Jan Albert ^d   Rohrer, Lucia ^a,b   Matile, Hugues ^e   Hornemann, Thorsten ^a,b   Stoffel, Markus ^b,c   Rentsch, Katharina M ^a,b   von Eckardstein, Arnold ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

ABCA1; ApoA I; ApoM; CETP; Endothelial lipase; HDL; Hepatic lipase; LCAT; SCARB1; Sphingosine 1 phosphate

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN M; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SPHINGOSINE 1 PHOSPHATE;

ALLELE; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; IN VIVO STUDY; LIPID METABOLISM; MALE; MONOGENIC DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; LINEAR MODELS; LIPASE; LIPID METABOLISM, INBORN ERRORS; LIPOCALINS; LYSOPHOSPHOLIPIDS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; PHENOTYPE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; SCAVENGER RECEPTORS, CLASS B; SPHINGOSINE; SWITZERLAND;

EID: 82955198484     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.08.049     Document Type: Article

References (30)

1. Fyrst H., Saba J.D. An update on sphingosine-1-phsophate and other sphingolipid mediators. Nat Chem Biol 2010, 6:489-497.
2. Rodriguez C., Gonzalez-Diez M., Badimon L., Martinez-Gonzalez J. Sphingosine-1-phosphate: a bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb Haemost 2009, 101:665-673.
3. Kim R.H., Takabe K., Milstien S., Spiegel S. Export and functions of sphingosine-1-phosphate. Biochim Biophys Acta 2009, 1791:692-696.
4. Sattler K., Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 2009, 82:201-211.
5. Nofer J.R., Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med 2005, 15(October (7)):265-271.
6. Tölle M., Pawlak A., Schuchardt M., et al. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008, 28(August (8)):1542-1548.
7. Keul P., Lucke S., von Wnuck Lipinski K., et al. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res 2011, 108(February (3)):314-323.
8. Axler O., Ahnström J., Dahlbäck B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res 2007, 48:1772-1780.
9. Christoffersen C., Nielsen L.B., Axler O., et al. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006, 47:1833-1843.
10. Wolfrum C., Poy M.N., Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005, 11:418-422.
11. Christoffersen C., Jauhiainen M., Moser M., et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem 2008, 283:1839-1847.
12. Sevvana M., Ahnström J., Egerer-Sieber C., et al. Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Mol Biol 2009, 393:920-936.
13. Christoffersen C., Obinata H., Kumaraswamy S.B., et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 2011, 108(June (23)):9613-9618.
14. von Eckardstein A. Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?. Expert Rev Cardiovasc Ther 2010, 8:345-358.
15. Weissglas-Volkov D., Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J Lipid Res 2010, 51:2032-2057.
16. Karuna R., Holleboom A.G., Motazacker M.M., et al. Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism. Atherosclerosis 2011, 214:448-455.
17. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955, 34:1345-1353.
18. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982, 28:1379-1388.
19. Bode C., Sensken S.C., Peest U., et al. Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J Cell Biochem 2010, 109:1232-1243.
20. Di Angelantonio E., Sarwar N., Perry P., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
21. Nordestgaard B.G., Tybjærg-Hansen A. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk. Curr Opin Lipidol 2011, 22(April (2)):113-122.
22. Negi S., Ballantyne C.M. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression. J Clin Lipidol 2010, 4(September-October (5)):365-370.
23. Nofer J.R., Bot M., Brodde M., et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007, 115(January (4)):501-508.
24. Argraves K.M., Sethi A.A., Gazzolo P.J., et al. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis 2011, 10(May (9)):70.
25. Sattler K.J., Elbasan S., Keul P., et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 2010, 105(November (6)):821-832.
26. Ohkawa R., Nakamura K., Okubo S., et al. Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation with red blood cell parameters. Ann Clin Biochem 2008, 45(July (Pt 4)):356-363. [PubMed PMID: 18583619].
27. Zhang B., Tomura H., Kuwabara A., et al. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis 2005, 178:199-205.
28. Huang R., Silva R.A., Jerome W.G., et al. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 2011, 18(April (4)):416-422.
29. Kontush A., Therond P., Zerrad A., et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007, 27:1843-1849.
30. Davidson W.S., Silva R.A., Chantepie S., et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009, 29:870-876.